VinTech Showcases AI Vision at FIX Trading Summit
Conceptual Preview of FIX AMA Underscores AI's Potential
HONG KONG, May 22, 2025 /PRNewswire/ -- VinTech, a leading provider of professional fintech and AI solutions, made a notable appearance today at the 23rd Asia Pacific Trading Summit hosted by the FIX Trading Community in Hong Kong. VinTech unveiled the concept for an AI-powered platform, FIX AMA (Ask Me Anything), a concept fully supported and developed by VinTech. The summit brought together over 600 trading and technology professionals from across the region to explore the latest trends in electronic trading.
The FIX (Financial Information eXchange) protocol is the global standard for electronic trading communications, adopted across equities, fixed income, forex, and derivatives markets. FIX Trading Community, the volunteer driven standards body behind the protocol, has shaped its global adoption and continuing innovation.
At the summit, VinTech showcased a range of innovations spanning both AI and fintech headlined by FIX AMA. Currently in its concept stage, FIX AMA is being designed to provide users with real-time, comprehensive and accurate technical support, powered by FIX's official golden source documentation. The platform aims to eliminate the need for manual searches through scattered documentation, saving time for FIX protocol users and significantly improving efficiency.
"We're excited to engage with industry leaders at the FIX Summit and share our vision for AI in financial communications," said Jay Law, Deputy CEO of VinTech. "The positive engagement and feedback we've received on this FIX AMA concept underscores the industry's growing demand for intelligent, protocol-aware support tools."
Ed Mangles, Asia Pacific Regional Director, FIX Trading Community added, "As the industry looks to AI to help solve for friction points across workflows and processes, the FIX Asia Pac community appreciates VinTech's forward-thinking approach to Al and their willingness to collaborate on ideas to help make FIX even more accessible and potentially unlock new possibilities for FIX through Al."
About VinTech
VinTech is a technology solutions provider with dual expertise in artificial intelligence and financial technology. Committed to building intelligent, secure, and scalable solutions, VinTech empowers financial institutions and enterprises to modernize operations, enhance decision-making, and accelerate digital transformation.
View original content:https://www.prnewswire.com/news-releases/vintech-showcases-ai-vision-at-fix-trading-summit-302463186.html
SOURCE VinTech
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Mystore Unveils Mystore Genie, an AI Agent Built On Google Cloud to Supercharge ONDC Network Buyer Journeys
GURUGRAM, India, June 3, 2025 /PRNewswire/ -- Mystore®, the first ONDC Network-connected marketplace, has launched Mystore Genie, an advanced AI Agent designed to transform how buyers discover and shop for products on the open network. Built on Google Cloud's Agentic AI framework, Mystore Genie empowers buyers with intuitive, conversational voice and text search capabilities that drive precise product discovery, making ordering easier and enabling sellers and brands to increase conversions through better product match accuracy. Unlike a generic chatbot, Mystore Genie goes beyond simple query handling. It leverages AI to understand search commands and user intent, delivering highly relevant, context-aware results in real time. This seamless conversational experience simplifies product discovery for buyers while boosting visibility and sales for sellers across the ONDC network. Mystore Genie's agentic capabilities also open new possibilities for enterprise brands across industries. This powerful AI model can be tailored into a sector-specific AI Agent for domains such as agriculture, banking, FMCG, automotive, and service-based industries, helping enterprises build intelligent digital touchpoints for enhanced customer engagement and operational efficiency. For a diverse country like India, with vast aspirational markets in Tier II-III cities and millions of first-time digital users, Mystore Genie can be a game-changing solution that simplifies product discovery for those less familiar with traditional internet search. Here's how Mystore's AI Agent, Mystore Genie, adds value to ONDC Network-connected brands and buyers: Delivers intelligent, conversational product search that accurately matches buyer intent to available products. Enhances buyer experience with a natural, interactive chat interface with product images and pricing that drives faster decisions and higher engagement. Reduces friction in ordering by simplifying product discovery and narrowing results based on context and preferences. Supports voice commands for adding to cart, changing address and placing purchases instantly. Increases conversions by showing granularly matched results, improving product visibility for sellers. Built on the Gemini Agentic AI framework by Google, offers a robust and scalable conversational AI backbone. It can be customised into dedicated Agents for diverse sectors and help brands reach target audiences better for sectors like AgriTech, Banking, Retail, Services, and more, enabling smart, domain-specific automation. "We have entered the Agentic AI era, and I am enthusiastic about the innovative applications our customers are developing and utilising with our AI models. Our partnership with ONDC and Mystore will significantly improve the interaction between buyers and sellers on the ONDC platform, ultimately expanding access to technology for Indians nationwide," said Mr. Bikram Singh Bedi, Vice President and Country MD at Google Cloud India. Highlighting the future-ready potential of Mystore Genie, Mr. Rajiv Kumar Aggarwal, CEO & Founder, Mystore, said, "We are at the cusp of a generational shift where AI will fundamentally redefine how commerce is discovered, accessed, and experienced. With Mystore Genie, built on Google Cloud's Agentic AI framework, we are not just enhancing search, we are reimagining digital interaction for a billion-plus population. This marks the beginning of truly inclusive, conversational commerce for India's vast aspirational and underserved markets. In the coming years, intelligent, sector-specific agents like Mystore Genie will become the primary digital interface across industries, bridging the digital divide, driving economic participation and shaping the next era of growth for enterprises." About Mystore Mystore® is an ONDC-connected marketplace that offers an unparalleled Ecommerce Ecosystem, enabling Enterprises and SMEs to leverage the ONDC network to accelerate their growth. Mystore specialises in setting up dealer-network-based Quick Commerce Marketplaces for brands in record time. With its AI-enabled ecommerce solutions for smart selling (using Mystore Seller App) and buying (through the Mystore Buyer App), Mystore empowers businesses to enhance discoverability, personalise experiences, and drive growth through the ONDC Network. Mystore's cutting-edge ecommerce solutions are built on MystoreNEXT (formerly StoreHippo®) - the leading enterprise ecommerce platform powering top enterprise brands across the globe for 10 years. Mystore enables hyperlocal businesses, SMEs, D2C brands, and Enterprises to join the ONDC Network ecosystem and explore the vast Indian markets. Proudly Made in Bharat and Built for Bharat, Mystore champions inclusivity by enabling regional sellers, local businesses, and digitally underserved communities to participate meaningfully in the Indian ecommerce ecosystem. Built on next-gen technology, PCI-DSS, SOC2, and ISO/IEC 27001 compliant, Mystore offers a level-playing field and 360-degree ecommerce solutions to businesses irrespective of their size and industry vertical. About ONDC: Incorporated on 31st December 2021, Open Network for Digital Commerce (ONDC), a Section 8 company, is an initiative of the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India to create a facilitative model that revolutionizes digital commerce, giving greater thrust to penetration of retail e-commerce in India. ONDC is not an application, platform, intermediary, or software but a set of specifications designed to foster open, unbundled, and interoperable Open Networks. Logo: View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
New Global Trade Benchmark: Envision Energy and Marubeni Sign Green Ammonia Offtake Agreement
CHIFENG, China, June 2, 2025 /PRNewswire/ -- Envision Energy, a global leader in green technology, announced a historic green ammonia offtake agreement with Marubeni Corporation, one of Japan's five major trading companies. This pioneering agreement on a global scale validates the commercial viability of green ammonia as a scalable energy solution, sets a global benchmark for its trade, and highlights the vast potential of green hydrogen-ammonia energy across the Asia-Pacific and beyond. The partnership brings together Envision Energy's leadership in integrated green hydrogen-ammonia solutions with Marubeni's expansive global network and energy trade expertise, facilitating large-scale production, supply, and commercialization of green ammonia. It aims to fast-track the global transition to low-carbon energy solutions, particularly in industries such as chemicals and fertilizers, driving sustainable growth across diverse sectors worldwide. This collaboration will also accelerate Japan's shift to a green economy, drive greater investment and innovation, and support the government's sustainability goals. "The global energy landscape is undergoing profound changes, with hydrogen-ammonia playing an increasingly pivotal role." said Mr. Frank Yu, Senior Vice President of Envision Energy, "Together with Marubeni, we are accelerating the commercialization of ammonia, turning it into a key energy solution that powers the world's transition to carbon-neutral fuels. This partnership lays the groundwork for ammonia-powered transportation and electricity generation, ultimately fostering a cleaner and more sustainable energy ecosystem." Envision Energy is the world's leading green hydrogen producer and the only company that possesses core technologies in renewable energy, hydrogen production, and net-zero industrial park, targeting for decarbonization at scale by green hydrogen-ammonia solutions. By pioneering full-stack green hydrogen technologies, including alkaline and PEM electrolysis technologies, along with its engineering competences and system integration capabilities, the company aims to address key challenges in the green hydrogen arena, particularly those related to efficiency and the intermittency of renewable energy sources. The company is at the forefront of developing the world's largest commercial green hydrogen-ammonia plant, leveraging its innovative net-zero industrial park model and full-stack green hydrogen technologies. Fully powered by green electricity from directly coupled wind and solar energy, the plant efficiently integrates wind, solar and storage with hydrogen-ammonia production to optimize costs and enhance sustainability. The initial production phase, launched in early 2024, targets 300,000 tons of green ammonia annually and plans to scale up to a total annual capacity of 1.5 million tons upon completion. Envision's outstanding contribution to decarbonization earned it the Energy Transition Changemaker Award at COP28 and recognition as an "Energy Innovator" on Fortune's Change the World list in 2024. View original content: SOURCE Envision Energy
Yahoo
an hour ago
- Yahoo
Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting
SUZHOU, China, June 3, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual Meeting of American Society of Clinical Oncology (2025 ASCO Annual Meeting) from May 30 to June 3, 2025, in Chicago, IL, U.S.. The results covered platinum-resistant ovarian cancer, HER2-positive breast cancer, and HER2-overexpressing gastrointestinal tumors. Title: JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trialsAbstract Number for Publication: 5557Session Type and Title: Poster Session - Gynecologic CancerSession Date and Time: 6/1/2025 9:00 AM-12:00 PM CDTPresenter: Xiaohua Wu, Fudan University Shanghai Cancer Center Methods JSKN003-101 (NCT05494918) is a Phase I study in Australia and JSKN003-102 (NCT05744427) is a Phase I/II study in China. Both trials enrolled patients with advanced solid tumors who were to receive JSKN003 monotherapy at various dose levels. Pooled results have demonstrated that JSKN003 monotherapy has promising efficacy signals in patients with PROC, and the efficacy was observed across patients with (IHC 1+/2+/3+) or without (IHC 0) HER2 expression, with or without prior bevacizumab and prior PARP inhibitor. Preliminary data from the pooled analysis of these two studies were presented at the 2024 European Society for Medical Oncology (ESMO) Congress for the first time. The latest findings for non-primary platinum-refractory PROC patients at a longer follow-up time were reported at this ASCO Annual Meeting. Results As of February 28, 2025, 46 PROC patients were enrolled and received JSKN003 every three weeks across five doses levels, among which 2 patients at the dose of 4.2 mg/kg, 2 patients at the dose of 5.2 mg/kg, 40 patients at the dose of 6.3 mg/kg (RP2D), 1 patient at the dose of 7.3mg/kg, and 1 patient at the dose of 8.4mg/kg. Efficacy: With a median follow-up time of 9.3 months, 46 patients were efficacy evaluable. 42 patients (91.3%) exhibited tumor shrinkage. The objective response rate (ORR) was 63.0%, the median progression-free survival (PFS) was 7.7 months, and the 9-month overall survival (OS) rate was 89.9%. Efficacy was observed across different HER2-expression subgroups. The ORR was 52.4% and the median PFS was 6.6 months in patients with HER2 IHC 0. The ORR reached 72.2% and the median PFS was 9.4 months in patients with HER2 expression (IHC 1+/2+/3+). Safety: Grade 3-4 treatment-related adverse events (TRAEs) occurred in 9 patients (19.6%). Serious TRAEs were reported in 6 patients (13.0%). No TRAEs leading to death. Interstitial lung disease (ILD) was observed in 5 patients (10.9%), all were Grade 1/2. Conclusions With extended follow-up, JSKN003 demonstrated robust PFS improvement in PROC, along with early signals of OS benefit. A confirmatory trial (JSKN003-306, NCT06751485) is currently enrolling all comers regardless of HER2 expression to validate JSKN003 as a treatment option for this patient population. Title: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studiesAbstract Number for Publication: 1028Session Type and Title: Poster Session - Breast Cancer - MetastaticSession Date and Time: 6/2/2025 9:00 AM-12:00 PM CDTPresenter: Yiqun Du, Fudan University Shanghai Cancer Center Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-positive (IHC 3+ or 2+/ISH+) advanced breast cancer from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, the median follow-up duration was 6.1 months. A total of 88 patients with HER2-positive breast cancer were enrolled, with the majority receiving 6.3 mg/kg or 8.4 mg/kg doses. The median age was 55 years (range: 32-79), with 77.3% ECOG PS 1. All patients had stage IV disease, with 76.1% having visceral metastases. All patients had prior anti-HER2 therapy, including 85.2% with prior ADCs or TKIs, and 55.7% having at least three prior lines treatment. Efficacy: A total of 80 T-DXd-naïve patients were enrolled, of whom 75 were evaluable for efficacy. In this population (N=75), JSKN003 demonstrated a confirmed ORR of 54.7% (95% CI: 42.7-66.2). The disease control rate (DCR) and clinical benefit rate (CBR) were 94.7% and 66.7%, respectively. Among 30 patients treated at the RP2D of 6.3 mg/kg, the confirmed ORR was 73.3%, and CBR reached 83.3%. Subgroup analyses by line of therapy showed ORRs of 66.7% in the prior first line group of 15 patients and 63.2% in the prior second line group of 19 patients, respectively. In addition, 8 patients who had previously received T-DXd were enrolled, among whom 7 had evaluable efficacy data. One patient achieved a partial response (PR), four had stable disease (SD), and tumor shrinkage was observed in four patients. These patients were analyzed separately for exploratory purposes. The median duration of response (DoR) in the overall population was 18.4 months (95% CI: 9.9-NE). Median PFS was not mature at the time of data cutoff. The 3-month and 6-month PFS rates were 88.4% (95% CI: 78.8–93.8) and 75.4% (95% CI: 62.3–84.4), respectively. Safety: 15.9% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 5.7% of patients. Dose reductions due to TRAEs occurred in 12.5% of patients, and one patient discontinued due to a TRAE. No TRAEs led to death. The most common TRAEs (≥20%) were nausea, increased alanine aminotransferase, decreased white blood cell count, vomiting, anemia, decreased appetite, thrombocytopenia, fatigue, neutropenia, and diarrhea. ILD was reported in 4 patients (4.5%), mostly Grade 1-2; one case was Grade 3. Conclusions JSKN003 demonstrated promising antitumor activity and manageable safety in heavily pretreated HER2-positive breast cancer, including patients previously treated with T-DXd. Its biparatopic HER2 antibody design may enhance target binding and contribute to the observed clinical benefit. A pivotal Phase III trial (JSKN003-301, NCT06846437) is ongoing to compare JSKN003 with T-DM1 in patients with HER2-positive advanced breast cancer who were previously treated with trastuzumab. Title: A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumorsAbstract Number for Publication: 3022Session Type and Title: Poster Session - Developmental Therapeutics - Molecularly Targeted Agents and Tumor BiologySession Date and Time: 6/2/2025 1:30 PM-4:30 PM CDTPresenter: Dan Liu, Beijing Cancer Hospital Methods The pooled analysis was performed to evaluate the efficacy and safety of JSKN003 in HER2-overexpressing (IHC 3+) metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJC) and colorectal cancer (CRC) patients from the Phase I clinical trial (JSKN003-101, NCT05494918) in Australia and the Phase I/II clinical trial (JSKN003-102, NCT05744427) in China. Results As of February 28, 2025, a total of 50 patients with HER2-overexpressing gastrointestinal tumors (27 patients in GC/GEJC and 23 patients in CRC) were enrolled and treated with JSKN003 monotherapy across 7 dose levels: 1 patient at the dose of 2.1 mg/kg, 1 patient at the dose of 4.2 mg/kg, 1 patient at the dose of 5.2 mg/kg, 43 patients at the dose of 6.3 mg/kg, 1 patient at the dose of 7.3 mg/kg, 2 patients at the dose of 8.4 mg/kg and 1 patient at the dose of 10.5 mg/kg. The median age was 60 years (range: 52-66), with 86.0% ECOG PS 1. Most patients were heavily pretreated: 38.0% had at least three lines of prior therapies, 68.0% received anti-HER2 therapy, 48.0% received Irinotecan. Efficacy: Among 48 patients who had at least one tumor assessment after baseline, JSKN003 demonstrated the ORR of 62.5% and the DCR was 93.8%. Among 27 patients with GC/GEJC, the ORR was 63.0% and DCR reached 92.6%. Among 21 patients with CRC, the ORR was 61.9% and DCR reached 95.2%. Among twenty patients with BRAF V600E-wild type, the ORR was 65.0%. Additionally, among 24 patients (4 patients in GC/GEJC and 20 patients in CRC) who were pretreated with irinotecan, the ORR achieved 58.3%. The median DoR in GC/GEJC patients was 9.6 months (95% CI: 3.0-NE), while the median DoR in CRC patients was 12.1 months (95% CI: 5.8-NE). Median PFS was 9.6 months (95%CI: 4.3, 11.6) with 70.4% PFS rate at 6 months in GC/GEJC patients. Median PFS was 13.8 months (95% CI: 6.8, NE) with 88.9% PFS rate at 6 months in CRC patients. Safety: 18.0% of patients experienced Grade 3 or higher TRAEs. Serious TRAEs were reported in 6.0% of patients. Dose reduction due to TRAEs occurred in 20.0% of patients and 16.3% at RP2D. No TEAEs led to discontinuation or death. The most common TRAEs (≥20%) were nausea, diarrhea, decreased appetite, decreased white blood cell count, anemia, fatigue, decreased neutrophil count, decreased platelet count and vomiting. ILD was reported in 3 patients (6.0%), with Grade 1 in 2 patients and Grade 2 in 1 patient. Conclusions JSKN003 demonstrated promising efficacy in heavily pretreated HER2-overexpressing (IHC3+) gastrointestinal tumors including patients previously treated with irinotecan, with a manageable and predictable safety profile. The HER2 biparatopic ADC design may contribute to the observed clinical benefit. About JSKN003 JSKN003 is a bispecific ADC developed based on KN026 using Alphamab's proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the "Field") in mainland China (excluding Hong Kong, Macau or Taiwan) (the "Territory") and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003. About Alphamab Oncology Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. The Company has one product approved for marketing (Envafolimab, the world's first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. View original content: SOURCE Alphamab Oncology Sign in to access your portfolio
